VintaBio, a life sciences company with expertise in viral vectors and cell and gene therapy development, has opened a custom-built manufacturing facility in Philadelphia. The company has also raised $64 million in funding and appointed David Radspinner as CEO.

VintaBio's $64 million in funding, led by Decheng Capital, helped support the development of its 22,500-sq-ft Philadelphia facility, designed specifically to streamline cell and gene therapy development and manufacturing.

Radspinner joins the company from ILC Dover, a New Mountain Capital portfolio company, where he served as president for the organization's biotherapeutics portfolio. Radspinner has spent nearly a decade leading the global marketing and sales efforts at top bioproduction companies including GE Healthcare Life Sciences (Cytiva) and Thermo Fisher Scientific.

Previously he was vice president of the Americas at Cytiva, a provider of life sciences products and services. Radspinner also worked at Eli Lilly & Co and Sanofi, developing analytical methodologies, drug products, and processes after receiving his PhD from the University of Arizona in Analytical Chemistry.